血红蛋白病治疗市场规模、份额、成长分析、按类型、按治疗类型、按最终用途、按地区 - 行业预测，2024-2031 年

2022 年，血红素病治疗的全球市场规模为 82.8 亿美元，从 2023 年的 93.2 亿美元成长到 2031 年的 240.9 亿美元，预计在预测期内（2024-2031 年）将成长。率为12.6%。

由于镰状细胞疾病和地中海贫血等疾病的治疗解决方案的进步，全球血红蛋白疾病治疗市场正在经历强劲增长。这些疾病以血红蛋白产生的遗传异常为特征，正在刺激基因治疗、干细胞移植和新药物治疗等技术创新，以纠正遗传异常并改善患者预后。不断加强的研发力道和策略伙伴关係正在加速新治疗方法的推出。此外，新兴市场意识的提高、政府的支持措施和医疗基础设施的改善也有助于市场扩张。然而，一些地区面临的挑战，例如治疗成本上升和获得先进治疗的机会有限，可能会阻碍进展。总体而言，市场有望显着成长，重点是个人化医疗以满足患者需求。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析
• 案例研究

血红素病治疗市场规模：按类型

• 市场概况
• 镰状细胞性贫血症
  • 镰状细胞性贫血
  • 镰状血红素C疾病
  • 镰状β地中海贫血
• 地中海型贫血
  • α地中海贫血
  • β地中海型贫血
• 其他血红蛋白疾病

血红素病治疗市场规模：依治疗类型

• 市场概况
• 输血
• 铁螯合疗法
• 骨髓移植
• 基因治疗
• 药物治疗
  • 羟基尿素
  • L-麸酰胺酸
  • 箱式机器人
  • 克里赞利珠单抗
  • 其他药品

血红素病治疗市场规模：依最终用途

• 市场概况
• 医院
• 专科诊所
• 门诊手术中心
• 研究/学术机构

血红素病治疗市场规模：按地区

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Sanofi SA（France）
• Global Blood Therapeutics, Inc.（USA）
• bluebird bio, Inc.（USA）
• Emmaus Life Sciences, Inc.（USA）
• Gamida Cell（Israel）
• Pfizer, Inc.（USA）
• Sangamo Therapeutics, Inc.（USA）
• CRISPR Therapeutics（Switzerland）
• Vertex Pharmaceuticals（USA）
• Novartis AG（Switzerland）
• Celgene Corporation（USA）
• Editas Medicine（USA）
• Bioverativ（USA）
• Protagonist Therapeutics（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol-Myers Squibb（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• Silence Therapeutics（UK）

结论和建议

Global Hemoglobinopathies Treatment Market size was valued at USD 8.28 billion in 2022 and is poised to grow from USD 9.32 billion in 2023 to USD 24.09 billion by 2031, growing at a CAGR of 12.6% during the forecast period (2024-2031).

The global hemoglobinopathies treatment market is experiencing robust growth, driven by advancements in therapeutic solutions for conditions like sickle cell disease and thalassemia. Characterized by genetic abnormalities in hemoglobin production, these disorders have spurred innovations such as gene therapy, stem cell transplantation, and new drug therapies, aimed at correcting genetic defects and improving patient outcomes. Increasing research and development efforts, along with strategic partnerships, are accelerating the introduction of novel treatments. Additionally, heightened awareness, supportive government initiatives, and enhanced healthcare infrastructure in emerging markets contribute to market expansion. However, challenges like high treatment costs and limited access to advanced therapies in certain regions may hinder progress. Overall, the market is set for significant growth, focusing on personalized medicine to meet patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemoglobinopathies Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented by type, treatment type, end-use and region. Based on type, the market is segmented into sickle cell disease, thalassemia and other hemoglobinopathies. Based on treatment type, the market is segmented into blood transfusion, iron chelation therapy, bone marrow transplantation, gene therapy and pharmacotherapy. Based on end-use, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers and research and academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemoglobinopathies Treatment Market

A significant driver of the global hemoglobinopathies treatment market is the growing emphasis on personalized medicine. This approach focuses on customizing treatment plans according to individual patient traits such as genetic profiles, disease severity, and therapeutic responses. Improvements in genetic testing and molecular diagnostics empower healthcare professionals to gain insights into the specific genetic mutations associated with hemoglobinopathies. Consequently, this understanding fosters the creation of targeted therapies and precision medicine strategies that enhance patient outcomes and satisfaction. The shift toward personalized medicine not only increases the effectiveness of existing treatments but also catalyzes the innovation of new therapeutic options tailored to individual needs.

Restraints in the Global Hemoglobinopathies Treatment Market

One of the significant challenges facing the global hemoglobinopathies treatment market is the exorbitant cost associated with advanced therapies. Innovative treatment options, including gene therapy and stem cell transplantation, require intricate procedures, specialized technology, and comprehensive post-treatment care, all of which escalate expenses considerably. This financial burden presents difficulties for both patients and healthcare systems, particularly in areas with limited medical resources and lower-income demographics. As a result, the high costs may restrict the adoption of these cutting-edge therapies, potentially creating inequities in healthcare delivery and outcomes for individuals suffering from hemoglobinopathies. Overcoming this financial barrier is essential to guarantee that all patients have access to effective treatment options.

Market Trends of the Global Hemoglobinopathies Treatment Market

The global hemoglobinopathies treatment market is witnessing a significant trend driven by the increasing focus on gene therapy as a revolutionary treatment modality. This trend is fueled by advancements in genetic engineering technologies, particularly CRISPR/Cas9, which facilitate precise correction of genetic mutations responsible for disorders such as sickle cell disease and thalassemia. As researchers and pharmaceutical companies intensify their efforts in R&D, numerous successful clinical trials and regulatory approvals are bolstering confidence in gene therapy's potential to rectify the underlying causes of these conditions. This shift towards innovative, targeted therapies positions gene therapy at the forefront of hemoglobinopathy treatment strategies, promising improved patient outcomes and a transformative impact on the market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Hemoglobinopathies Treatment Market Size by Type & CAGR (2024-2031)

• Market Overview
• Sickle Cell Disease
  • Sickle Cell Anemia
  • Sickle Hemoglobin-C Disease
  • Sickle Beta-Thalassemia
• Thalassemia
  • Alpha Thalassemia
  • Beta Thalassemia
• Other Hemoglobinopathies

Global Hemoglobinopathies Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Blood Transfusion
• Iron Chelation Therapy
• Bone Marrow Transplantation
• Gene Therapy
• Pharmacotherapy
  • Hydroxyurea
  • L-Glutamine
  • Voxelotor
  • Crizanlizumab
  • Other Drugs

Global Hemoglobinopathies Treatment Market Size by End-Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research and Academic Institutes

Global Hemoglobinopathies Treatment Market Size & CAGR (2024-2031)

• North America (Type, Treatment Type, End-Use)
  • USA
  • Canada
• Europe (Type, Treatment Type, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Blood Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emmaus Life Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silence Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations